Get started

Financials · MGX

Metagenomi Therapeutics Inc. (MGX) financials

For the twelve months ended Mar 31, 2026, Metagenomi Therapeutics Inc. reported $22.33M of revenue and -$85.89M of net income.

Revenue, TTM
$22.33M
Revenue growth, YoY
-50.7%
Net income, TTM
-$85.89M
Net margin
-384.6%
Free cash flow, TTM
-$87.54M
EPS, diluted, TTM
-$2.29
Cash
$39.03M
P/S
1.22
Market cap
$27.2M
Annual revenue$25.21M
FY2023FY2025
Annual net income-$87.87M
FY2023FY2025
Annual free cash flow-$89.47M
FY2023FY2025

MGX revenue and earnings growth

MGX revenueQ1 2026$1.25M

Quarter YoY
-69.8%
QoQ
-68.1%
FY YoY
-51.8%

MGX revenue was $1.25M in fiscal Q1 2026 (ended Mar 31, 2026), down 69.8% from a year earlier and down 68.1% from the prior quarter. For the full fiscal 2025 it was $25.21M, down 51.8% from fiscal 2024.

MGX net incomeQ2 2026-$27.48M

MGX net income was -$27.48M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$19.91M a year earlier. For the full fiscal 2025 it was -$87.87M, compared with -$78.06M in fiscal 2024.

MGX EPSQ2 2026-$0.73

MGX diluted EPS was -$0.73 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.54 a year earlier. For the full fiscal 2025 it was -$2.36, compared with -$2.36 in fiscal 2024.

MGX free cash flowQ2 2026-$19.64M

MGX free cash flow was -$19.64M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$21.38M a year earlier. For the full fiscal 2025 it was -$89.47M, compared with -$112.19M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
Revenue$25.21M$52.30M$44.76M
Research and development$94.43M$109.18M$94.40M
Selling, general and admin$26.79M$32.02M$28.84M
Operating income-$96.01M-$88.90M-$78.49M
Pre-tax income-$87.93M-$83.57M-$60.23M
Income tax-$58.0K-$5.51M$8.03M
Net income-$87.87M-$78.06M-$68.25M
EPS, basic-$2.36-$2.36-$20.05
EPS, diluted-$2.36-$2.36-$20.05
Diluted shares37.3M33.0M3.4M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
Cash and equivalents$41.72M$32.63M$145.85M
Receivables$305.0K$1.26M$2.45M
Current assets$165.54M$257.96M$278.27M
Total assets$221.10M$324.60M$364.84M
Current liabilities$22.93M$37.31M$68.86M
Total liabilities$62.51M$89.74M$149.67M
Shareholders' equity$158.60M$234.86M-$135.58M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
Operating cash flow-$88.89M-$109.07M-$91.41M
Capital expenditures$574.0K$3.11M$9.81M
Free cash flow-$89.47M-$112.19M-$101.22M
Investing cash flow$103.53M-$88.16M$45.73M
Financing cash flow-$356.0K$84.01M$1.01M
Stock-based compensation$11.85M$16.20M$6.92M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
Revenue growth, YoY-51.8%16.8%-
Operating margin-380.9%-170.0%-175.4%
Net margin-348.5%-149.3%-152.5%
Free cash flow margin-354.9%-214.5%-226.2%
Return on equity-55.4%-33.2%-
Return on assets-39.7%-24.0%-18.7%
Current ratio7.226.914.04

Source: XBRL data Metagenomi Therapeutics Inc. files with the SEC, latest filing dated Aug 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

MGX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
MGX$22.33M-50.7%-$85.89M-384.6%$27.2M
AMGN$38.90B+8.2%$9.39B24.1%$251.65B
GILD$30.99B+6.5%-$3.86B-12.5%$210.01B
MRNA$2.52B+13.1%-$2.79B-110.5%$107.39B
ARGX$4.25B+88.6%$1.29B30.4%$59.72B
RVMD$0--$1.13B-$43.29B
BIIB$10.30B+2.3%$347.50M3.4%$37.67B
BNTX€2.87B+4.3%-€1.14B-39.6%$21.98B
EXEL$2.50B+9.1%$885.14M35.5%$17.51B

MGX FAQ

8 questions
  • What is MGX revenue?
    Metagenomi Therapeutics Inc. (MGX) reported $22.33M of revenue for the twelve months ended Mar 31, 2026. That is down 50.7% from the year before. Revenue for fiscal 2025 was $25.21M.
  • Is MGX profitable?
    No. Metagenomi Therapeutics Inc. reported a net loss of $85.89M for the twelve months ended Mar 31, 2026.
  • How much cash and debt does MGX have?
    Metagenomi Therapeutics Inc. reported $39.03M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is MGX revenue growing?
    Metagenomi Therapeutics Inc.'s revenue changed -51.8% in fiscal 2025, to $25.21M.
  • What is MGX free cash flow?
    Metagenomi Therapeutics Inc. generated -$87.54M of free cash flow for the twelve months ended Mar 31, 2026, which is operating cash flow of -$87.22M less capital expenditures.
  • What is MGX earnings per share?
    Diluted earnings per share were -$2.29 for the twelve months ended Mar 31, 2026, from SEC filings, restated for any stock split those filings show.
  • When did MGX last report financial results?
    The latest statements here come from Metagenomi Therapeutics Inc.'s 10-Q filed on Aug 10, 2026, covering the period ended Jun 30, 2026.
  • Where does this MGX financial data come from?
    Quantisnow builds these statements from the structured XBRL data Metagenomi Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.